CANGENE

Cangene is a fully integrated developer and manufacturer of immune therapeutics. Our first drug, WinRho® SDF, has been commercially available since 1980, and since then we have established a solid track record of developing and commercializing plasma-derived products that address multiple therapeutic areas. Our current product portfolio consists of purified, concentrated antibody preparations (hyperimmunes) with target applications in infectious disease, hematology, transplantation and biodefense. Four of our hyperimmune products are approved in the United States and/or Canada, and three products are included in the U.S. Strategic National Stockpile. We are committed to the safety and quality of our products, the service of our customers, and the interests of our shareholders.